Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001683168-25-004168
Filing Date
2025-06-02
Accepted
2025-06-02 19:46:09
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 6161
2 JOINT FILING AGREEMENT bristol_ex01.htm EX-1 5975
  Complete submission text file 0001683168-25-004168.txt   14249
Mailing Address 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94111
Business Address 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94111 (800) 304-9888
GT Biopharma, Inc. (Subject) CIK: 0000109657 (see all company filings)

EIN.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-32837 | Film No.: 251016837
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 89 NEXUS WAY CAMANA BAY, PO BOX 311063 GRAND CAYMAN E9 KY1-1205
Business Address 89 NEXUS WAY CAMANA BAY, PO BOX 311063 GRAND CAYMAN E9 KY1-1205 (310) 331-8485
BRISTOL INVESTMENT FUND LTD (Filed by) CIK: 0001174866 (see all company filings)

EIN.: 000000000
Type: SCHEDULE 13G/A